Prevalence of APA at enrollment and 1 and 7 months after enrollment
| . | Enrollment . | 1 month . | 7 month . | Twice . | Once (tested twice) . | Once (tested once) . |
|---|---|---|---|---|---|---|
| ACA | 22 of 296 | — | 21 of 250 | 16 of 242 | 6 of 242 | 5 of 62 |
| IgG | 12 of 296 | — | 10 of 250 | 8 of 242 | 2 of 242 | 4 of 62 |
| IgM | 11 of 296 | — | 11 of 249 | 8 of 241 | 2 of 241 | 2 of 62 |
| IgG and IgM | 1 of 296 | — | 0 of 249 | 0 of 241 | 0 of 241 | 1 of 62 |
| Anti-β2GP1 | 3 of 296 | — | 2 of 250 | 2 of 242 | 1 of 242 | 0 of 62 |
| LA | — | 41 of 227 | 39 of 175 | 17 of 162 | 27 of 162 | 19 of 78 |
| APTT | — | 12 of 226 | 13 of 175 | 6 of 162 | 10 of 162 | 3 of 77 |
| DRVV | — | 35 of 226 | 33 of 173 | 14 of 159 | 21 of 159 | 18 of 78 |
| APTT and DRVV | — | 6 of 225 | 7 of 173 | 3 of 159 | 5 of 159 | 2 of 77 |
| . | Enrollment . | 1 month . | 7 month . | Twice . | Once (tested twice) . | Once (tested once) . |
|---|---|---|---|---|---|---|
| ACA | 22 of 296 | — | 21 of 250 | 16 of 242 | 6 of 242 | 5 of 62 |
| IgG | 12 of 296 | — | 10 of 250 | 8 of 242 | 2 of 242 | 4 of 62 |
| IgM | 11 of 296 | — | 11 of 249 | 8 of 241 | 2 of 241 | 2 of 62 |
| IgG and IgM | 1 of 296 | — | 0 of 249 | 0 of 241 | 0 of 241 | 1 of 62 |
| Anti-β2GP1 | 3 of 296 | — | 2 of 250 | 2 of 242 | 1 of 242 | 0 of 62 |
| LA | — | 41 of 227 | 39 of 175 | 17 of 162 | 27 of 162 | 19 of 78 |
| APTT | — | 12 of 226 | 13 of 175 | 6 of 162 | 10 of 162 | 3 of 77 |
| DRVV | — | 35 of 226 | 33 of 173 | 14 of 159 | 21 of 159 | 18 of 78 |
| APTT and DRVV | — | 6 of 225 | 7 of 173 | 3 of 159 | 5 of 159 | 2 of 77 |
| . | Enrollment . | 1 month . | 7 month . | Any time* . | . | . |
|---|---|---|---|---|---|---|
| APA+(≥1 tests) | 23 of 296 | 41 of 227 | 54 of 250 | 80 of 307 | ||
| 1 assay only† | 21 of 296 | NA | 47 of 250 | 69 of 307 | ||
| ACA + anti-β2GP1 | 2 of 296 | NA | 0 of 250 | 0 of 307 | ||
| ACA + LA | NA | NA | 6 of 250 | 9 of 307 | ||
| Anti-β2GP1 + LA | NA | NA | 0 of 250 | 0 of 307 | ||
| ACA + anti-β2GP1 + LA | NA | NA | 1 of 250 | 2 of 307 |
| . | Enrollment . | 1 month . | 7 month . | Any time* . | . | . |
|---|---|---|---|---|---|---|
| APA+(≥1 tests) | 23 of 296 | 41 of 227 | 54 of 250 | 80 of 307 | ||
| 1 assay only† | 21 of 296 | NA | 47 of 250 | 69 of 307 | ||
| ACA + anti-β2GP1 | 2 of 296 | NA | 0 of 250 | 0 of 307 | ||
| ACA + LA | NA | NA | 6 of 250 | 9 of 307 | ||
| Anti-β2GP1 + LA | NA | NA | 0 of 250 | 0 of 307 | ||
| ACA + anti-β2GP1 + LA | NA | NA | 1 of 250 | 2 of 307 |
APTT, activated partial thromboplastin time; DRVV, dilute Russell viper venom; NA, not applicable.
The number of each APA assay performed at each of the 3 time points is shown in the upper part of this table.
IgG and IgM subgroups of ACA and APTT and DRVV subgroups of LA were not counted as separate assays.